LCM
PTCT icon

Laurion Capital Management’s PTC Therapeutics PTCT Stock Holding History

Laurion Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,200
Closed -$311K – 1162
2019
Q3 		$311K Buy
+9,200
New +$400K ﹤0.01% 860
2018
Q2 		– Sell
-130,323
Closed -$3.53M – 1536
2018
Q1 		$3.53M Buy
+130,323
New +$3.3M 0.03% 460
2017
Q2 		– Sell
-35,100
Closed -$345K – 1822
2017
Q1 		$345K Buy
+35,100
New +$425K ﹤0.01% 1035

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Laurion Capital Management's PTCT Position: Q4 2019 in Review

Laurion Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 9,200 shares — an estimated $311K sold.

Laurion Capital Management first reported a position in PTCT in Q1 2017 and held it in 3 quarters. The position peaked at $3.53M in Q1 2018. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

  • Laurion Capital Management reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Laurion Capital Management sold 9,200 PTC Therapeutics shares in Q4 2019, an estimated $311K.
  • Laurion Capital Management first reported a position in PTC Therapeutics in Q1 2017 and held it in 3 quarters.
  • Laurion Capital Management's PTC Therapeutics position peaked at $3.53M in Q1 2018.
  • 206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Laurion Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.